# US 2017/0247327 A1 · Octahydrocyclopentapyrroles, their preparation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0247327 A1
- Document ID: US20170247327A1
- Status: Published application
- Kind: A1
- Application number: 15/457,821
- Filed: 2017-03-13
- Published: 2017-08-31
- Earliest claimed: 2013-03-14
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: Konstantin Petrukhin; Christopher Cioffi; Graham Johnson; Nicoleta Dobri; Emily Freeman; Ping Chen; Michael Conlon; Lei Zhu
- Web page: https://patentgrep.com/patent/US20170247327A1

## CPC

- C07D 209/52: condensed with a ring other than six-membered
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 27/02: Ophthalmic agents
- C07D 209/02: condensed with one carbocyclic ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.

## Claims

### Claim at position 1

-114. (canceled)

### Claim 115

A compound having the structure:
wherein
ψ is absent or present, and when present is a bond;
R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl;
R6 is absent or present, and when present is H, OH, or halogen;
A is absent or present, and when present is
B is substituted or unsubstituted heteromonocycle or heterobicycle;
and
wherein when ψ is present, then R6 is absent and when ψ is absent, then R6 is present,
or a pharmaceutically acceptable salt thereof.

### Claim 116 (depends on 115)

The compound of claim 115 having the structure:

### Claim 117 (depends on 115)

The compound of claim 115 having the structure:

### Claim 118 (depends on 115)

The compound of claim 115, wherein B has the structure:
wherein
n is 1;
R7 is H, C1-C4 alkyl, or oxetane;
Y1, Y2 and Y4 are each CH2 or C(CH3)2; and
Y3 is O, SO2, or N—R10,
wherein
R10 is H, C1-C4 alkyl, C1-C4 cycloalkyl, (C1-C4 alkyl)-CF3, (C1-C4 alkyl)-OCH3, (C1-C4 alkyl)-halogen, SO2—(C1-C4 alkyl), SO2—(C1-C4 alkyl)-CF3, SO2—(C1-C4 alkyl)-OCH3, SO2—(C1-C4 alkyl)-halogen, C(O)—(C1-C4 alkyl), C(O)—(C1-C4 alkyl)-CF3, C(O)—(C1-C4 alkyl)-OCH3, C(O)—(C1-C4 alkyl)-halogen, C (O)—NH—(C1-C4 alkyl), C (O)—N (C1-C4 alkyl)2, (C1-C4 alkyl -C(O)OH, C (O)—NH2 or oxetane.

### Claim 119 (depends on 118)

The compound of claim 118, wherein B has the structure:
wherein
R10 is H, C1-C4 alkyl, C1-C4 cycloalkyl, (C1-C4 alkyl)-CF3, (C1-C4 alkyl)-OCH3, (C1-C4 alkyl)-halogen, SO2—(C1-C4 alkyl), SO2—(C1-C4 alkyl)-CF3, SO2—(C1-C4 alkyl)-OCH3, SO2—(C1-C4 alkyl)-halogen, C(O)—(C1-C4 alkyl), C(O)—(C1-C4 alkyl)-CF3, C(O)—(C1-C4 alkyl)-OCH3, C(O)—(C1-C4 alkyl)-halogen, C (O)—NH—(C1-C4 alkyl), C(O)—N(C1-C4 alkyl)2, (C1-C4 alkyl)-C(O)OH, C(O)—NH2 or oxetane.

### Claim 120 (depends on 119)

The compound of claim 119,
wherein R10 is C(O)—CH3, C(O)—CH2CH3, C(O)—CH2CH2CH3, C(O)—CH(CH3)2, C(O)—CH2CH(CH3)2, C(O)-t-Bu, C (O)—CH2OCH3, C(O)—CH2CF3, C(O)—CH2Cl, C(O)—CH2F, C(O)—CH2CH2OCH3, C(O)—CH2CH2CF3, C(O)—CH2CH2Cl, C(O)—CH2CH2F,

### Claim 121 (depends on 115)

The compound of claim 115, wherein B has the structure:
wherein
Y1, Y2, Y3 and Y4 are each independently CR8 or N, wherein each R8 is independently H, halogen, C1-C4 alkyl, C1-C4 cycloalkyl, O(C1-C4 alkyl), CN, CF3, C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3, or NHC(O)—N(CH3)2.

### Claim 122 (depends on 121)

The compound of claim 121, wherein B has the structure:
wherein each R8 is independently H, halogen, C1-C4 alkyl, C1-C4 cycloalkyl, O(C1-C4 alkyl), CN, CF3, C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3, or NHC(O)—N(CH3)2.

### Claim 123 (depends on 122)

The compound of claim 122, wherein B has the structure:
wherein each R8 is independently H, halogen, C1-C4 alkyl, C1-C4 cycloalkyl, O(C1-C4 alkyl), CN, CF3, C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3, or NHC(O)—N(CH3)2.

### Claim 124 (depends on 122)

The compound of claim 122,
wherein each R8 is independently H, Cl, Br, F, OCH3, OCH2CH3, CF3, CN, CH3, CH3CH3, C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3, NHC(O)—NHCH3, NHC(O)—N(CH3)2, SO2—NHCH3 or SO2—N(CH3)2.

### Claim 125 (depends on 123)

The compound of claim 123,
wherein R8 is H, Cl, Br, F, OCH3, OCH2CH3, CF3, CN, CH3, CH3CH3, C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3, NHC(O)—NHCH3, NHC(O)—N(CH3)2, SO2—NHCH3 or SO2—N(CH3)2.

### Claim 126 (depends on 115)

The compound of claim 115, wherein B has the structure:
wherein R21, R22, R23, R24, and R25 are each independently
H, halogen CN, CF3, OH, NH2, C1-C10 alkyl, C3-C6 cycloalkyl, O(C1-C10 alkyl), C(O)NH2, C(O)NH(C1-C10 alkyl), C(O)N(C1-C4 alkyl)2, C(O)OH, C(O)O(C1-C10 alkyl), C(O)(C1-C10 alkyl), C(O)NH(SO2)—(C1-C10 alkyl), C(O)NH(SO2)—(C3-C6 cycloalkyl), C(O)NH(SO2)-(aryl), O(SO2)—NH2, NHC(O)—NH(C1-C10 alkyl), NHC(O)—N(C1-C4 alkyl)2, SO2—(C1-C10 alkyl).

### Claim 127 (depends on 126)

The compound of claim 126, wherein B has the structure:
wherein R21, R22, R24 and R25 are each independently
H, halogen, OH, NH2, C1-C4 alkyl, C3-C6 cycloalkyl, O(C1-C4 alkyl), C(O)NH2, C(O)NH(C1-C4 alkyl), C(O)N(C1-C4 alkyl)2, C(O)OH, C(O)O(C1-C4 alkyl), C(O)(C1-C4 alkyl), C(O)NH(SO2)—(C1-C4 alkyl), C(O)NH(SO2)—(C3-C6 cycloalkyl), C(O)NH(SO2)-(aryl), or O(SO2)—NH2, SO2—(C1-C4 alkyl).

### Claim 128 (depends on 126)

The compound of claim 126, wherein B has the structure:
wherein R22 and R24 are each independently
H, halogen, OH, NH2, C1-C4 alkyl, C3-C6 cycloalkyl, O(C1-C4 alkyl), C(O)NH2, C(O)NH(C1-C4 alkyl), C(O)N(C1-C4 alkyl)2, C(O)OH, C (O)O(C1-C4 alkyl), C(O)(C1-C4 alkyl), C(O)NH(SO2)—(C1-C4 alkyl), C(O)NH(SO2)—(C3-C6 cycloalkyl), C(O)NH(SO2)-(aryl), or O(SO2)—NH2, SO2—(C1-C4 alkyl).

### Claim 129 (depends on 127)

The compound of claim 127, wherein R21, R22, R24 and R25 are each independently H, F, Cl, CF3, CH3, OCH3, OH, SO2—CH3, C (O)NH2, C(O)OH, C(O)OCH3,

### Claim 130 (depends on 128)

The compound of claim 128, wherein R22 and R24 are each independently H, F, Cl, CF3, CH3, OCH3, OH, SO2—CH3, C(O)NH2, C(O)OH, C(O)OCH3,

### Claim 131 (depends on 126)

The compound of claim 126, wherein B has the structure

### Claim 132 (depends on 115)

A pharmaceutical composition comprising the compound of claim 115 and a pharmaceutically acceptable carrier.

### Claim 133 (depends on 115)

A method for treating a disease characterized by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith comprising administering to the mammal an effective amount of the compound of claim 115.

### Claim 134 (depends on 133)

The method of claim 133, wherein the disease characterized by excessive lipofuscin accumulation in the retina is Age-Related Macular Degeneration,dry (atrophic) Age-Related Macular Degeneration, Stargardt Disease, Best disease, adult vitelliform maculopathy or Stargardt-like macular dystrophy.
